Skip to content Skip to menu

Medicines Australia announces Interim CEO

Tuesday, 27 March 2018

Media Release

The Board of Medicines Australia, the peak body representing the innovative medicines industry has today announced the appointment of Elizabeth de Somer, as the Interim CEO of Medicines Australia (MA).

Ms de Somer will commence in the role effective Tuesday, 3 April, following the resignation of Milton Catelin, who is returning to the UK.

Medicines Australia Chair Mr Wes Cook, congratulated Ms de Somer on her appointment as Interim CEO.

“Ms de Somer takes on this role with the full support of the MA Board and senior management team,” said Mr Cook.

“I am confident she will provide continuity, stability and strong leadership for both MA and our stakeholders until a permanent appointment is made,” he said.

“Ms de Somer is the current Director Policy & Research within the secretariat and has had a long and successful career within Medicines Australia, having worked within the organisation since 2007. Ms de Somer is highly respected both inside and outside the medicines industry due to ongoing contributions.”

“Medicines Australia is incredibly well positioned to contribute to the development of good health policy in Australia.”

“I’d also like to thank Milton Catelin, who has been in the role since October 2016. Milton has done a tremendous job working with the Board, the secretariat and our members to continue building on strong and meaningful partnerships with our stakeholders,” said Mr Cook.

The MA Board Nominations Sub-Committee has appointed Brooker Consulting to run the recruitment process for a permanent CEO.


More information: Natalie Wimmer – Communications Manager, Medicines Australia
Ph: 0450 728 660


As COVID19 continues to spread, our thoughts go out to anyone who has been infected or impacted. We hope that you are taking the necessary precautions to keep safe and well, both at work and at home.

Medicines Australia continues to monitor the situation and take advice from the Department of Health and the World Health Organisation. We are focused on responding to the important short-term issues but are also ensuring we stay balanced and maintain a focus on the medium and long-term business for our industry along with the well-being of our people.

At Medicines Australia we have initiated the following to ensure we support containment measures to provide business continuity and the well-being of our staff.

  • All non-essential travel has been restricted or cancelled
  • All face-to-face meetings (with external stakeholders and members) have been changed to virtual meetings (where appropriate)
  • Staff have been provided with the latest official information on COVID-19 through a hot-link on the office intranet; this information is regularly monitored and updated
  • Flexible working arrangements are covered in our HR policy which will allow staff to work remotely, if or when required
  • Current IT infrastructure enables staff to work remotely and will be in use if any person needs to self-isolate
  • Visual reminders have been displayed around the office, providing information about best hygiene practices
  • Extra hand-sanitiser, tissues and cleaning products have been supplied to staff for their work spaces

Our latest information is located at